REG - Diaceutics PLC - Contract with leading life sciences company

DiaceuticsAnnouncement

14/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220214:nRSN5095Ba&default-theme=true

RNS Number : 5095B  Diaceutics PLC  14 February 2022

14 February 2022

 

Diaceutics PLC

("Diaceutics" or "the Company" or "the Group")

 

US$2.5m contract with leading life sciences company

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is
pleased to announce that it has secured a three year data subscription
contract with a top five global life sciences company worth in excess
of $2.5m, to be recognised over the course of the contract. This is the
Company's largest data subscription contract to date, adding to the Group's
growing levels of recurring revenues.

Under the contract, Diaceutics will deliver real-world data and insights on
the demand for biomarkers across a number of diseases and therapy brands. This
information will help the customer to identify trends and gaps in the adoption
of biomarkers, to support the commercialisation of new and existing
diagnostics for Precision Medicines.

The contract further demonstrates the demand from leading life science
companies for real-world data and insights to support sales and marketing
initiatives and is an endorsement of the quality of the insights that the DXRX
platform can provide.

The data will be supplied via DXRX, the world's first platform to support the
commercialisation of Precision Medicine. DXRX uses machine learning to
integrate and analyse real-world, real time diagnostic testing data from a
global network of laboratories to identify current gaps within the diagnostic
landscape. Diaceutics then provides services over the platform to enhance the
level of testing at the front line, quickly.

 

Peter Keeling, CEO and Founder of Diaceutics PLC, commented: "The adoption of
Precision Medicine continues apace and those Pharma companies leading the way
are embedding real world testing data in their planning to identify where the
patients who could benefit from better testing and better treatment are
currently being missed.

"Through DXRX, we can not only provide the insights but also the solution -
using our platform network to directly improve testing at the front line,
maximising the revenue opportunity for Pharma.

"This significant contract adds to a strong start to the year and demonstrates
the ability of the DXRX platform to improve the quality and long-term
visibility of the revenues of the business."

 

Enquiries:

 

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer               Via Alma PR
 Philip White, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

 

 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTKZGMZLFDGZZM